镥-177 PSMA 治疗胶质母细胞瘤的安全性与可行性
这项前瞻性单臂先导试验纳入 10 例标准治疗后进展/持续的胶质母细胞瘤患者,经 99mTc-PSMA SPECT/低剂量 CT 评估后接受 2–6 周期 100–150 mCi 的 177Lu-PSMA 治疗,未观察到血液学或肾脏毒性,9/10 例临床改善或稳定,6 个月和 1 年生存率分别为 100% 和 80%。
要点
- 进展/持续胶质母细胞瘤患者接受 177Lu-PSMA 治疗未见血液学或肾脏毒性。
- 10 例中 9 例临床改善或稳定,MRI 显示 3 例部分缓解、4 例稳定、3 例进展。
- 首剂后 6 个月和 1 年生存率分别为 100% 和 80%。
核心结论
- 177Lu-PSMA 治疗可能是进展/持续胶质母细胞瘤安全且潜在有效的挽救治疗,需进一步专门研究以确定更精确的选择标准、治疗方案和时机。
研究设计与样本
- 前瞻性单臂先导临床试验,纳入 10 例标准治疗中进展/持续的胶质母细胞瘤患者。
- 经 99mTc-PSMA SPECT/低剂量 CT 评估合格后,接受 2–6 周期 100–150 mCi 治疗,间隔 4–5 周。
- 通过定期血液学和肾功能检查、临床病史与检查评估毒性,并用 MRI 评估疗效。
主要发现
- 23 例被转诊患者中最终 10 例入选并接受 3–6 周期 177Lu-PSMA 治疗。
- 未观察到血液学或肾脏毒性。
- 临床改善或稳定见于 9/10 例患者。
- 治疗前后 MRI 比较显示 3 例部分缓解、4 例稳定、3 例进展。
- 首剂 177Lu-PSMA 治疗后 6 个月和 1 年生存率分别为 100% 和 80%。
关键数值与推荐
- 治疗剂量为每周期 100–150 mCi,间隔 4–5 周,共 2–6 周期。
- 入组前以 99mTc-PSMA SPECT/低剂量 CT 评估资格。
临床怎么用
- 对标准治疗后进展/持续的胶质母细胞瘤,可考虑 177Lu-PSMA 作为挽救治疗选项。
- 治疗前应通过 99mTc-PSMA SPECT/低剂量 CT 评估资格。
- 治疗期间需定期监测血液学和肾功能,并用 MRI 评估疗效。
局限性
- 单臂先导试验样本量小(10 例),结果需进一步专门研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most common primary malignant tumor of the brain with high morbidity and mortality without an effective therapeutic option currently. This study aimed to evaluate the feasibility and safety of [ 177 Lu] Lu-prostate-specific membrane antigen (PSMA) therapy in patients with progressive/persistent refractory glioblastoma. PATIENTS AND METHODS: This is a prospective single-arm pilot clinical trial with inclusion of 10 patients with progressive/persistent GBM on standard of care therapy. After evaluation of eligibility by [ 99m Tc] Tc-PSMA single-photon emission computed tomography (SPECT)/ low-dose CT, the patients received 2-6 cycles of 100-150 mCi with 4-5 weeks interval, and toxicity was assessed with regular hematologic and renal function tests as well as clinical history and examination. The response to therapy was also evaluated with magnetic resonance imaging (MRI). RESULTS: Among 23 patients who were referred for this trial, 10 patients finally were included and received 3-6 cycles [ 177 Lu] Lu-PSMA therapy. No hematologic or renal toxicity was noted. Clinical improvement or stability was seen in 9/10 patients. The comparison of MRI before and after therapy revealed 3 patients with partial response, 4 patients with stable disease and 3 patients with progressive disease. Six-month and 1-year survival rates were 100% and 80% after first dose of [ 177 Lu] Lu-PSMA therapy. CONCLUSIONS: This study demonstrated that [ 177 Lu] Lu-PSMA therapy could be a safe and potentially effective salvage therapy in the progressive/persistent GBM and should be more evaluated with further dedicated study to assess more precise selection criteria and therapeutic protocol and timing.
引用
- Ghaedian T, Alipour A, Rakhsha A, et al. Safety and Feasibility of [ 177 Lu] Lu-PSMA Therapy in Glioblastoma. Clin Nucl Med. 2026. PMID: 41543452. doi:10.1097/RLU.0000000000006219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。